search
Back to results

Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis. (CITRUSEP)

Primary Purpose

Sepsis

Status
Unknown status
Phase
Phase 1
Locations
Mexico
Study Type
Interventional
Intervention
Citrulline malate
Sponsored by
Instituto Mexicano del Seguro Social
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis focused on measuring sepsis, citrulline, endothelial, toxemia, endothelial determination of progression, with vs without citrulline

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Sepsis
  • Severe sepsis
  • Diagnosis of sepsis in the first 36 hours of hospitalization.
  • Informed Consent
  • Intestinal tract intact

Exclusion Criteria:

  • Terminal cancer
  • Acute and chronic liver diseases
  • Chronic renal failure.
  • Acute renal failure AKIN III.
  • Pregnant and postpartum women
  • Dying patients.
  • Patients with cardiac arrest.
  • Active gastrointestinal bleeding.
  • Steroids or immunosuppressants.
  • Enrolled in another study intervention.
  • Citrulline allergy.

Sites / Locations

  • CME Centro Mèdico Siglo XXIRecruiting
  • CME La RazaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Intervention

Placebo

Arm Description

Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA

10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA

Outcomes

Primary Outcome Measures

Multiple organ failure
Progression to multiple organ failure ending in death

Secondary Outcome Measures

Full Information

First Posted
February 18, 2015
Last Updated
August 26, 2015
Sponsor
Instituto Mexicano del Seguro Social
search

1. Study Identification

Unique Protocol Identification Number
NCT02370030
Brief Title
Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.
Acronym
CITRUSEP
Official Title
Controlled Randomized Multi-centric Clinical Trial on the Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Unknown status
Study Start Date
November 2014 (undefined)
Primary Completion Date
June 2016 (Anticipated)
Study Completion Date
December 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Instituto Mexicano del Seguro Social

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Triple blind placebo-controlled study to determine if administering citrulline in patients with sepsis and severe sepsis slows progression to multiple organ failure and death, measuring biomarkers of endothelial dysfunction. Patients are divided into placebo or citrulline and followed up for 1 month.
Detailed Description
Consecutive patients with sepsis are being recited from intensive care unite of IMSS at the CMN Siglo XXI and CMN La Raza over the period of november 2015 through june 2016. After signing an informed consent they will be randomized into 80 for intervention arm and 80 for the placebo arm. All patients will receive usual medical treatment; and during seven days citurlline arm subjects will receive supplementation with oral or nasogastric citrulline (10 g/day), while other group patients will receive during seven days oral or nasogastric placebo (10 g/day) with no visible difference between these. Microalbuminuria and interleukines 1, 6, and 10 will be measured at randomization and at day 7. All subjects will be followed for 28 days, and after the follow-up period results will be analyzed to determine de efficacy and safety of citrulline, primary outcome are the incidence of multiple organic failure and death, also microalbuminuria levels 1,6,10-interleukines. We will use Student-t and Chi2 for statistical analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
Keywords
sepsis, citrulline, endothelial, toxemia, endothelial determination of progression, with vs without citrulline

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Active Comparator
Arm Description
Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
Intervention Type
Dietary Supplement
Intervention Name(s)
Citrulline malate
Other Intervention Name(s)
Citrulline
Intervention Description
Active comparator: 10 g/day citrulline malate during 7 days
Primary Outcome Measure Information:
Title
Multiple organ failure
Description
Progression to multiple organ failure ending in death
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Sepsis Severe sepsis Diagnosis of sepsis in the first 36 hours of hospitalization. Informed Consent Intestinal tract intact Exclusion Criteria: Terminal cancer Acute and chronic liver diseases Chronic renal failure. Acute renal failure AKIN III. Pregnant and postpartum women Dying patients. Patients with cardiac arrest. Active gastrointestinal bleeding. Steroids or immunosuppressants. Enrolled in another study intervention. Citrulline allergy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eduardo Almeida Gutierrez, MSc
Phone
+52-55-5627-6900
Ext
21230
Email
almeida_90210@yahoo.com.mx
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eduardo Almeida Gutierrez, MSc
Organizational Affiliation
Coordinación de Investigación en Salud, México.
Official's Role
Study Director
Facility Information:
Facility Name
CME Centro Mèdico Siglo XXI
City
Mexico City
State/Province
DF
ZIP/Postal Code
06720
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leonor Serrano, MS
Phone
+52-55-5627-6900
Ext
21445
Email
leotigger40@hotmail.com
Facility Name
CME La Raza
City
Mexico City
State/Province
DF
Country
Mexico
Individual Site Status
Recruiting

12. IPD Sharing Statement

Citations:
PubMed Identifier
19105791
Citation
Kao CC, Bandi V, Guntupalli KK, Wu M, Castillo L, Jahoor F. Arginine, citrulline and nitric oxide metabolism in sepsis. Clin Sci (Lond). 2009 Jun 2;117(1):23-30. doi: 10.1042/CS20080444.
Results Reference
result
PubMed Identifier
17662768
Citation
Barr FE, Tirona RG, Taylor MB, Rice G, Arnold J, Cunningham G, Smith HA, Campbell A, Canter JA, Christian KG, Drinkwater DC, Scholl F, Kavanaugh-McHugh A, Summar ML. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg. 2007 Aug;134(2):319-26. doi: 10.1016/j.jtcvs.2007.02.043.
Results Reference
result
PubMed Identifier
20084502
Citation
Piton G, Manzon C, Monnet E, Cypriani B, Barbot O, Navellou JC, Carbonnel F, Capellier G. Plasma citrulline kinetics and prognostic value in critically ill patients. Intensive Care Med. 2010 Apr;36(4):702-6. doi: 10.1007/s00134-010-1751-6.
Results Reference
result
PubMed Identifier
23782971
Citation
Piton G, Belon F, Cypriani B, Regnard J, Puyraveau M, Manzon C, Navellou JC, Capellier G. Enterocyte damage in critically ill patients is associated with shock condition and 28-day mortality. Crit Care Med. 2013 Sep;41(9):2169-76. doi: 10.1097/CCM.0b013e31828c26b5.
Results Reference
result
PubMed Identifier
19056593
Citation
Luiking YC, Poeze M, Ramsay G, Deutz NE. Reduced citrulline production in sepsis is related to diminished de novo arginine and nitric oxide production. Am J Clin Nutr. 2009 Jan;89(1):142-52. doi: 10.3945/ajcn.2007.25765. Epub 2008 Dec 3.
Results Reference
result
PubMed Identifier
23612995
Citation
Kao C, Hsu J, Bandi V, Jahoor F. Alterations in glutamine metabolism and its conversion to citrulline in sepsis. Am J Physiol Endocrinol Metab. 2013 Jun 15;304(12):E1359-64. doi: 10.1152/ajpendo.00628.2012. Epub 2013 Apr 23.
Results Reference
result
PubMed Identifier
22666356
Citation
Wijnands KA, Vink H, Briede JJ, van Faassen EE, Lamers WH, Buurman WA, Poeze M. Citrulline a more suitable substrate than arginine to restore NO production and the microcirculation during endotoxemia. PLoS One. 2012;7(5):e37439. doi: 10.1371/journal.pone.0037439. Epub 2012 May 29.
Results Reference
result
PubMed Identifier
23327349
Citation
Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW, Wheeler AP, Bernard GR, Summar ML. Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis. Crit Care. 2013 Jan 17;17(1):R10. doi: 10.1186/cc11934.
Results Reference
result
PubMed Identifier
23509945
Citation
Cynober L. Citrulline: just a biomarker or a conditionally essential amino acid and a pharmaconutrient in critically ill patients? Crit Care. 2013 Mar 11;17(2):122. doi: 10.1186/cc12534.
Results Reference
result

Learn more about this trial

Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.

We'll reach out to this number within 24 hrs